Urinary albumin-to-creatinine ratio was more strongly associated with adverse kidney outcomes in pediatric patients compared with urine protein-to-creatinine ratio, according to study data published in Nephrology Dialysis Transplantation.
Pediatric nephrology practices often use urinary protein-to-creatinine ratio (UPCR) over urinary albumin-to-creatinine ratio (UACR) as a marker for chronic kidney disease progression due to its lower cost and feasibility, according to Franz Schaefer, MD, professor of pediatrics and chief of pediatric nephrology at Heidelberg University Hospital in Germany,

A clinical practice guideline communication from the Endocrine Society raised concerns about the real-world applicability of a new framework for diagnosing obesity released last year.
As Healio previously reported, The Lancet Diabetes & Endocrinology Commission released a report in January 2025 that proposed a new approach for diagnosing obesity. Among the changes proposed by the commission were using body fat measurements to diagnose obesity alongside BMI, and a separate diagnosis of preclinical obesity for adults with no signs or symptoms of reduced organ or tissue function.

DENVER — Rademikibart, a next-generation immunomodulator, was associated with long-term disease control for people with moderate to severe eczema, according to a presentation at the American Academy of Dermatology Annual Meeting.
“These data are significant because they demonstrate that rademikibart delivers rapid, deep and durable disease control in adults and adolescents with moderatetosevere atopic dermatitis across a full year of treatment,” Cheng Zhou, MD, professor and chair of the department of dermatology at Peking University People’s Hospital in Beijing, told Healio.
AD affects

NEW ORLEANS — People who exercise in the morning may lower their likelihood of developing cardiometabolic disease compared with those who exercise later during the day or in the evening, a speaker reported.
Exercising earlier in the day may be a simple behavioral modification that can further lower cardiometabolic risk among people who already exercise regularly, according to a presentation at the American College of Cardiology Scientific Session.
“While we have a strong evidence base on how much people should exercise, we know very little about whether when people exercise matters,”

A proprietary monoclonal antibody targeting an inhibitory immune checkpoint pathway had favorable safety and tolerability in adults with early Alzheimer’s disease, according to topline phase 1b study results.
“For clinicians, these findings signal that the therapeutic landscape for Alzheimer’s disease may be broadening beyond amyloid-targeting therapies,” Catherine J. Mummery, MBBS, PhD, FRCP, professor of neurology at University College London, director of NIHR UK Dementia Trials Network and principal investigator, told Healio about the data presented at the 2026 Alzheimer’s & Parkinson’s

The care that older adults with advanced cancer receive often does not align with their preferences and values, study findings suggest.
When asked to prioritize living longer or maintaining quality of life, patients about to start a new systemic treatment chose the latter by an 8-to-1 margin.
However, rates of upfront treatment modifications and downstream clinical outcomes — such as survival, incidence of serious adverse events or hospitalization rates — did not vary based on preference.
“This is a reality check for all of us, because routine care may not be prioritizing outcomes that matter

A pivotal trial of obinutuzumab has demonstrated the strongest evidence yet of the efficacy of B-cell depletion in systemic lupus erythematosus, according to researchers who published their findings in the New England Journal of Medicine.
“Starting several decades ago, the lupus community strongly believed that B-cell depletion was a biologically sound strategy to reduce lupus disease activity,” Richard A. Furie, MD, chief of rheumatology at Northwell Health, in Great Neck, New York, told Healio. “However, early trials, such as EXPLORER and LUNAR, that evaluated rituximab , failed to